Biomarkers for Hepatocellular Carcinoma

Overview

Journal Biomark Cancer

Publisher Sage Publications

Date 2017 May 5

PMID 28469485

Citations 61

Authors

Jiatao Lou

Lingfei Zhang

Shaogang Lv

Chenzi Zhang

Shuai Jiang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Here, we review on our current understanding of HCC biomarkers.

Citing Articles

Identification of Bioactive and Anticancer Properties of Bidens Pilosa in-vitro Evidence.

Said W, Khattab A, Hamed S, Abo El-Maaty S, Khalil H Asian Pac J Cancer Prev. 2024; 25(10):3551-3558.

PMID: 39471021 PMC: 11711352. DOI: 10.31557/APJCP.2024.25.10.3551.

Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis.

Ou Z, Fu S, Yi J, Huang J, Zhu W Oncol Lett. 2024; 28(5):536.

PMID: 39290959 PMC: 11406626. DOI: 10.3892/ol.2024.14669.

PGK1 is a potential biomarker for early diagnosis and prognosis of hepatocellular carcinoma.

Yi J, Luo X, Huang W, Yang W, Qi Y, He J Oncol Lett. 2024; 27(3):109.

PMID: 38304170 PMC: 10831403. DOI: 10.3892/ol.2024.14242.

A new portable toluidine blue/aptamer complex-on-polyethyleneimine-coated gold nanoparticles-based sensor for label-free electrochemical detection of alpha-fetoprotein.

Yaiwong P, Anuthum S, Sangthong P, Jakmunee J, Bamrungsap S, Ounnunkad K Front Bioeng Biotechnol. 2023; 11:1182880.

PMID: 37284243 PMC: 10239980. DOI: 10.3389/fbioe.2023.1182880.

Key Members of the CmPn as Biomarkers Distinguish Histological and Immune Subtypes of Hepatic Cancers.

Abou-Fadel J, Reid V, Le A, Croft J, Zhang J Diagnostics (Basel). 2023; 13(6).

PMID: 36980321 PMC: 10047786. DOI: 10.3390/diagnostics13061012.

References

Hosny G, Farahat N, Tayel H, Hainaut P . Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases. Cancer Lett. 2008; 264(2):201-8. DOI: 10.1016/j.canlet.2008.01.031. View

Weber G . The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics. 2011; 8(6):263-88. View

Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G . CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016; 11(3):e0151501. PMC: 4792431. DOI: 10.1371/journal.pone.0151501. View

Marrero J, Feng Z, Wang Y, Nguyen M, Befeler A, Roberts L . Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137(1):110-8. PMC: 2704256. DOI: 10.1053/j.gastro.2009.04.005. View

Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P . Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000; 31(4):302-8. DOI: 10.1097/00004836-200012000-00007. View

Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P . SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005; 117(3):506-9. DOI: 10.1002/ijc.21189. View

Ahn J, Sung H, Yoon Y, Kim B, Yang W, Lee C . Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics. 2013; 13(1):30-48. PMC: 3879622. DOI: 10.1074/mcp.M113.028621. View

Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V . Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J Gastroenterol Hepatol. 2014; 29(8):1637-44. DOI: 10.1111/jgh.12576. View

Kladney R, Cui X, Bulla G, Brunt E, Fimmel C . Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002; 35(6):1431-40. DOI: 10.1053/jhep.2002.32525. View

10.

Chan K, Lai P, Mok T, Chan H, Ding C, Yeung S . Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008; 54(9):1528-36. DOI: 10.1373/clinchem.2008.104653. View

11.

Filmus J . The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J. 2003; 19(4-5):319-23. DOI: 10.1023/A:1025312819804. View

12.

Naraki T, Kohno N, Saito H, Fujimoto Y, Ohhira M, Morita T . gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta. 2002; 1586(3):287-98. DOI: 10.1016/s0925-4439(01)00107-7. View

13.

Di Tommaso L, Franchi G, Park Y, Fiamengo B, Destro A, Morenghi E . Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007; 45(3):725-34. DOI: 10.1002/hep.21531. View

14.

Lokman N, Ween M, Oehler M, Ricciardelli C . The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011; 4(2):199-208. PMC: 3170418. DOI: 10.1007/s12307-011-0064-9. View

15.

Yeo W, Wong N, Wong W, Lai P, Zhong S, Johnson P . High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005; 25(2):266-72. DOI: 10.1111/j.1478-3231.2005.01084.x. View

16.

Sung Y, Hwang S, Park M, Farooq M, Han I, Bae H . Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003; 94(3):259-62. PMC: 11160150. DOI: 10.1111/j.1349-7006.2003.tb01430.x. View

17.

Wong I, Lo Y, Yeo W, Lau W, Johnson P . Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res. 2000; 6(9):3516-21. View

18.

Qin L . Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med. 2014; 8(1):24-32. DOI: 10.1007/s11684-014-0312-8. View

19.

Sterling R, Jeffers L, Gordon F, Venook A, Reddy K, Satomura S . Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2008; 7(1):104-13. DOI: 10.1016/j.cgh.2008.08.041. View

20.

Kuzmanov U, Kosanam H, Diamandis E . The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med. 2013; 11:31. PMC: 3751898. DOI: 10.1186/1741-7015-11-31. View